NanoString debuts products to push COVID-19 research

By The Science Advisory Board staff writers

June 17, 2020 -- NanoString Technologies has debuted new products that advance COVID-19 research by studying the immune response of the SARS-CoV-2 virus.

The company's nCounter host response gene expression panel and COVID-19 panel plus spike-in provide comprehensive analyses of the viral infection and immune response. New protein and RNA content available on the GeoMx digital spatial profiler enables analysis of key biological pathways mapped to specific regions within infected tissues, according to NanoString.

The company demonstrated at the LabRoots Coronavirus Virtual Conference on June 17 that applying these new tools in SARS-CoV-2 formalin-fixed paraffin-embedded (FFPE) tissue samples helped better understand the processes underlying infection, pathogenesis, and therapeutic response.

Accelerating COVID-19 drug repurposing with computers, organ chips
The U.S. Defense Advanced Research Projects Agency (DARPA) has awarded the Wyss Institute for Biologically Inspired Engineering at Harvard University...
San Diego research institutes study spread of COVID-19
San Diego medical and scientific research institutes launched a large-scale COVID-19 screening research study with an initial focus on evaluating healthcare...
Saiba selects AGC to manufacture COVID-19 vaccine
Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.
Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.
New repository may speed COVID-19 drugs to market
As researchers race to find vaccines and treatments for COVID-19, drug repurposing has emerged as potentially the fastest route to get drugs to market....

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter